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Purpose: To identify preoperative computed tomography (CT)
findings associated with thymoma invasiveness before surgical re-
section and with clinical outcome.
Methods:We retrospectively reviewed CT scans of 99 patients with
thymoma surgically treated at our institution between September
1999 and April 2010. Chest CT findings documented were size,
volume, and heterogeneity of primary tumor; abutment of medias-
tinal vessels; and presence of calcifications, lobulation, infiltration of
fat surrounding tumor, adjacent pulmonary changes, adenopathy,
and pleural nodularity.
Results: Our study group consisted of 53 (54%) men and 46 (46%)
women, age 18–79 years (mean: 53.2 years). Masaoka pathologic
stages were stage I for 10 (10%), stage II for 48 (48%), stage III for
21 (21%), and stage IV for 20 (20%). The median radiologic tumor
size was 7 cm (range: 2.5–21 cm). A multivariable logistic regres-
sion model showed that primary tumors with prechemotherapy
radiologic tumor size7 cm (odds ratio [OR]: 3.18, 95% confidence
interval [CI]: 1.16–8.67, p  0.02), a lobulated tumor contour (OR:
8.20, 95% CI: 1.63–41.35, p 0.01), and infiltration of surrounding
fat (OR: 3.76, 95% CI: 1.45–9.78, p  0.007) were more likely to
have stage III or IV disease. Cox’s proportional hazard model
showed that the presence of pulmonary nodules on staging CT was
the only imaging parameter associated with shorter progression-free
survival (hazard ratio: 4.93, 95% CI: 1.60–15.17,
p  0.005) and overall survival (p  0.03).
Conclusion: The primary tumor CT imaging features can differen-
tiate between stage I/II and stage III/IV disease and, thus, help
identify patients more likely to benefit from neoadjuvant therapy.
Key Words: Thymoma, Computed tomography, Staging, Neoadju-
vant therapy.
(J Thorac Oncol. 2011;6: 1274–1281)
Thymomas are the most common primary neoplasm of theanterior mediastinum but account for less than 1% of
malignancies in adults.1 Their classification and staging have
evolved over the past decades. The World Health Organiza-
tion (WHO) classification system proposed in 1999 has been
found to lack adequate reproducibility and clinical predictive
value.2 The Masaoka staging system,3,4 which is based on the
gross and microscopic invasive properties of the tumor at
surgery, is the most widely used system in clinical practice
and in prospective clinical trials and has been shown to
strongly correlate with prognosis.2,4,5 Patients with thymomas
who are obviously locally advanced at presentation typically
receive neoadjuvant chemotherapy to enable effective resec-
tion,5,6 as complete resection, even of advanced disease,
improves survival.3,7 Recent reports suggest that neoadjuvant
therapy provides a survival advantage compared with adju-
vant therapy for patients with stage III thymomas,8–10 but
distinguishing Masaoka stage III disease from stage II dis-
ease, which does not need neoadjuvant therapy, requires
postoperative pathologic examination. Thus, the postopera-
tive Masaoka staging system and its variants cannot be used
to guide decisions about neoadjuvant therapy.4,11
The purpose of our study was to identify preoperative
computed tomography (CT) findings associated with thy-
moma invasiveness—Masaoka stage—and survival. Such
findings could serve as a guide to distinguish patients with
thymoma with locoregional invasion who may benefit from




For this retrospective study, we reviewed the Univer-
sity of Texas MD Anderson Cancer Center’s computerized
radiology database to identify patients referred for chest CT
or positron emission tomography-CT to evaluate thymoma
between September 1, 1999, and April 5, 2010. We then
reviewed these patients’ computerized medical records to
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extract data on demographic characteristics, presence of my-
asthenia gravis, weight loss, and performance status (deter-
mined using the American Society of Anesthesiologists
scale). We also reviewed the pathology and operative reports
of each patient to determine whether they underwent resec-
tion and to determine the final diagnosis. Of the 354 patients
referred for thymoma evaluation by chest CT, 255 were
excluded because their preoperative chest CT scans were not
available for review (n  95), their pathology slides were not
available for confirmation of the diagnosis (n  67), review
of the pathology report revealed they had a tumor other than
thymoma (n  70), or their thymoma was not resected (n 
23). Thus, the final study group composed of 99 patients who
were surgically treated for thymoma and who had pathology
slides and preoperative CT scans available for review.
This study was approved by the institutional review
board of our cancer center, and we obtained a waiver of
informed consent. In addition, our study was in compliance
with Health Insurance Portability and Accountability Act
regulations.
Staging
We assigned a Masaoka pathologic stage4 to each
patient by reviewing the operative report and pathology
report in consultation with an experienced pathologist spe-
cializing in thymoma (C.A.M.). Briefly, stage I was assigned
when the tumor was completely encapsulated; stage II when
there was either microscopic invasion into the capsule (IIb) or
macroscopic invasion into surrounding fat or mediastinal
pleura (IIa); stage III when there was macroscopic invasion
into a neighboring organ such as the pericardium, great
vessels, or lung; and stage IV when there was pleural or
pericardial dissemination (IVa) or lymphatic/hematogenous
metastasis (IVb). WHO classification12 for each tumor was
determined (C.A.M.) from the operative specimen and was
divided into atypical thymoma (WHO type B3) and thymoma
(WHO type A to B2) for statistical purposes.2,13
Imaging
Chest CT scans had been obtained using a variety of
helical scanners and slice thicknesses: 1.25 mm (n  4), 2
mm (n 2), 2.50 mm (n 42), 3 mm (n 4), 3.75 mm (n
9), 5 mm (n  28), 7 mm (n  5), 7.5 mm (n  2), 8 mm
(n  1), or 10 mm (n  2). Images had been reconstructed
using lung and soft tissue kernels. In 87 patients, intravenous
nonionic contrast medium (120–150 ml Optiray 320;
Mallinckrodt Inc., Hazelwood, MO) had been administered
by an antecubital vein at a rate of 3.0 to 4.2 ml/s with a 12-
to 20-second delay.
The staging chest CT scans were reviewed by two chest
radiologists with 12 and 11 years of experience (E.M.M. and
M.A.M., respectively), while they were blinded to the clinical
information. Differences in their findings were resolved by
consensus. Eighty-five studies were reviewed using soft copy,
and the remaining 14 were evaluated using printed images.
Imaging findings recorded for each patient were size of
the primary tumor in three perpendicular diameters; estimated
tumor volume; tumor homogeneity or heterogeneity; tumor
lobularity or roundness; tumor calcifications; whether there
was a fat plane separating the tumor from nearby blood
vessels; whether tumor abutted 50% of circumference of
vessels; infiltration of the fat abutting the tumor; and the
presence of a pleural effusion, pleural nodularity, mediastinal
adenopathy (defined as short axis 1 cm), pulmonary nod-
ules, upper abdominal metastases, and bone metastases.
For reporting of tumor size, the largest of the three
diameters was used. For calculation of estimated tumor
volume, the three radii (r) were calculated by halving the




   rlat rap rz·.
Statistical Analyses
A logistic regression model was used to estimate the
probability (p) that a patient had stage III or IV thymoma.
The modeling was first done in a univariable fashion; then
all the covariates with a p value less than 0.10 were included
in the multivariable model, and backward selection was used
to obtain the final model.
A regression tree was used to assess the best cutoff size
to distinguish stage I/II from stage III/IV. All parameters that
were significant (p  0.05) on multivariable analysis were
then used to construct a nomogram for stage III/IV disease.
We used the method of Kaplan and Meier14 to estimate
the median overall survival and progression-free survival.
Cox’s15 proportional hazards regression model was then used
to test the statistical significance of several potential prog-
nostic factors for overall survival and progression-free sur-
vival. This modeling was done in a univariable fashion. From
this model, we estimated the hazard ratio (HR) for each
potential prognostic factor along with a 95% confidence
interval (CI). Again, all potential prognostic factors with a p
value less than 0.10 from the univariable analysis were
included in a saturated model, and backward elimination was
used to remove factors from the model based on the likeli-
hood ratio test in the multiple regression analysis.
The statistical software used to construct the nomo-
gram was S-PLUS version 8.1 (TIBCO Software Inc., Palo
Alto, CA) with the rpart library. The other statistical
analyses were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC).
RESULTS
Patient and Disease Characteristics
Of the 99 study patients, 53 (54%) were men and 46
(46%) were women. Their ages ranged from 18 to 79 years
(mean: 53.2 years). Twenty-six (27%) had weight loss, and
10 (10%) had myasthenia gravis. The American Society of
Anesthesiologists performance status score was 1 to 3 in 93
patients (93%) and 4 to 5 in 6 (6%). The Masaoka disease
stage was stage I in 10 patients (10%), stage IIa in 33 patients
(33%), stage IIb in 15 patients (15%), stage III in 21 patients
(21%), stage IVa in 17 patients (17%), and stage IVb in three
patients (3%). WHO classification was type A in 17 (17%),
type AB in 9 (9%), type B1 in 24 (24%), type B2 in 27 (27%),
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and type B3 in 22 (22%) patients. Initial staging chest CT
scans were obtained at a median of 104 days (range: 7–267
days) before surgery. For the 73 patients who had more than
one CT study before surgery, the last chest CT study before
surgery was obtained a median of 19 days (range: 1–73 days)
before surgery. The median radiologic tumor size at presen-
tation was 7 cm (range: 2.5–21 cm). Thirty-seven patients
(37%) received cisplatin-based neoadjuvant therapy (median:
3 courses, range: 1–6 courses). Before chemotherapy, the
median radiologic tumor volume was 99.73 cm3 (range:
4.61–2507 cm3). After chemotherapy, the median tumor
volume was 75.45 cm3 (range: 4.61–2069 cm3). For the 62
patients who did not receive neoadjuvant chemotherapy, the
median radiologic tumor volume was 46.08 cm3 (range:
4.61–860 cm3).
Radiologic Features Associated with Stage
Several radiologic features of the primary tumor
showed a significant association with Masaoka stage III/IV
disease. Larger tumor size, both before and after chemother-
apy, was associated with stage III/IV disease, an association
that was consistent (p  0.0001). Extreme sizes were partic-
ularly useful for differentiating stage III/IV from stage I/II
disease. Only one (4%) of the 24 tumors less than 5 cm was
stage III/IV, and only three (20%) of the 15 tumors more than
12 cm were stage I/II.
A regression tree model was constructed based on the
ability of maximal tumor diameter to predict stage III/IV
disease. This showed the best cutoff value to be 7.15 cm.
Thus, we used 7 cm as the cutoff value for maximal tumor
diameter for further analyses and nomogram construction.
Univariable analysis also showed that stage III/IV disease
was associated with primary tumors that were lobulated
(p  0.001), were heterogeneous (p  0.0004), had cal-
cifications within them (p  0.04), infiltrated surrounding
mediastinal fat (p  0.0002), abutted 50% of circumfer-
ence of vessels (p  0.0007), or resulted in adjacent lung
changes (p  0.0001). Pleural effusion (p  0.01), pleural
nodularity (p  0.001), WHO type B3 (p  0.02), and
younger age (p  0.04) were also associated with stage
III/IV disease (Table 1; Figures 1 and 2).
Multivariable logistic regression model of the primary
tumor variables showed that only tumor size, infiltration of
surrounding fat, and lobularity of the tumor were associated
with the risk of having stage III/IV thymoma. Patients with
7 cm tumors before chemotherapy were more likely to have
stage III/IV disease than patients with less than 7 cm tumors
(odds ratio [OR]: 3.18, 95% CI: 1.16–8.67, p  0.02).
Patients with infiltration of surrounding fat were more likely
to develop stage III/IV thymoma than patients without infil-
tration of surrounding fat (OR: 3.76, 95% CI: 1.45–9.78, p 
0.007); patients with a lobulated tumor were more likely to
have higher stage disease than patients with a round tumor
(OR: 8.20, 95% CI: 1.63–41.35, p  0.01).
A clinical nomogram was then constructed based on
tumor size at presentation (7 cm or 7 cm), presence of a
lobulated tumor, and infiltration of fat surrounding the tumor
(Figure 3). Internal validation using the bootstrap method
with 200 repetitions yielded a bias-corrected concordance
index of 0.795 with an optimism of 0.009. Receiver operating
characteristic curve analysis demonstrated that the nomogram
was accurate in predicting stage III/IV disease (area under the
curve: 80%) (Figure 4).
To overcome possible downstaging of the 37 patients
who received neoadjuvant therapy, as 18 (48%) were found
to have stage I/II disease, univariable analysis of those who
did not receive neoadjuvant therapy (n  62) showed that
stage III/IV disease remained associated with primary tumors
that were 7 cm (p  0.001), lobulated (p  0.01), heter-
ogenous (p  0.03), had calcifications (p  0.04), were
associated with infiltrated surrounding mediastinal fat (p 
0.007), or resulted in adjacent lung changes (p  0.001).
When evaluating the imaging parameters that may
signify distant metastatic disease (stage IVa or IVb), univar-
iate analysis showed that pleural nodularity (p  0.001),
pleural effusion (p  0.01), and mediastinal lymphadenopa-
thy (p  0.03) were associated with stage III/IV disease but
not pulmonary nodules (p  0.06). Multivariable analysis of
these distant disease parameters in conjunction with the
primary tumor parameters showed that only pleural nodular-
ity (p  0.002) and tumor 7 cm (p  0.04) remained
significant.
Because all patients with pleural nodularity (n  22)
had stage III/IV disease, to assess which CT parameters of the
primary tumor signify advanced disease when the pleura
appears normal, we then studied the 77 patients without
pleural nodularity. In patients presenting with a normal ap-
pearing pleura, univariable analysis showed that CT factors
associated with stage III were tumor size 7 cm (p  0.03),
primary tumors that are lobulated (p  0.04), heterogeneous
(p  0.01), have calcifications within them (p  0.04),
infiltrate surrounding mediastinal fat (p  0.02), abut  50%
of circumference of vessels (p  0.02), or result in adjacent
lung changes (p 0.02). Nevertheless, multivariable analysis
showed that in this group of patients, only infiltration of the
surrounding fat (OR: 3.59; 95% CI: 1.02–12.60; p  0.04)
and tumor heterogeneity (OR: 0.14; 95% CI: 0.03–0.67; p 
0.01) remained associated with stage III disease.
Tumor Classification Associated with
Radiologic Features and Stage
WHO type B3 was associated with advanced disease
(stage III/IV) (p 0.02). Of the imaging parameters assessed
(Table 1), the only imaging parameter that WHO type B3
tumors were associated with was large tumor size (p  0.02),
as 17 of the 22 (77%) patients with type B3 tumors had a
primary tumor 7 cm.
Survival
Patients were followed up for a mean of 40 months
(range: 3.1–131.7 months) after CT presentation. Within
this follow-up period, 28 patients had progression of dis-
ease and 10 died.
Cox’s proportional hazard model showed that the pres-
ence of pulmonary nodules (p 0.0002), pulmonary changes
adjacent to the primary tumor (p  0.006), mediastinal
adenopathy (p  0.0005), lobularity of the tumor (p  0.02),
tumor abutting 50% of mediastinal vessels (p  0.02),
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TABLE 1. Association of CT Features and Other Factors with Risk of Stage III/IV Thymoma
Variables
Overall No. of Patients








Tumor size before chemotherapya
7 cm 44 (9) — — 1.00 —
7 cm 54 (31) 1.657 0.0004 5.24 2.11–13.02
Calcification
No 69 (24) — — 1.00 —
Yes 30 (17) 0.448 0.04 2.45 1.02–5.89
Homogeneous
No 63 (35) — — 1.00 —
Yes 36 (6) 0.916 0.0004 0.16 0.06–0.44
Roundness
Round 24 (2) — — 1.00 —
Lobulated 75 (39) 1.239 0.001 11.92 2.62–54.31
Fat plane separating tumor from vessels
No 87 (39) — — 1.00 —
Yes 12 (2) 0.701 0.08 0.25 0.05–1.19
Infiltration of surrounding fat
No 56 (14) — — 1.00 —
Yes 43 (27) 0.811 0.0002 5.06 2.13–12.02
Adjacent lung changes
No 68 (19) — — 1.00 —
Yes 31 (22) 0.921 0.0001 6.30 2.47–16.13
Degree of abutment of vessel circumference
50% 72 (24) — — 1.00 —
50% 20 (16) 1.040 0.0007 8.00 2.41–26.57
Presence of any effusion
No 80 (28) — — 1.00 —
Yes 19 (13) 0.696 0.01 4.02 1.38–11.74
Lymphadenopathyb
No 91 (33) — — 1.00 —
Yes 8 (8)
Pulmonary nodules
No 91 (35) — — 1.00 —
Yes 8 (6) 0.784 0.06 4.80 0.92–25.12
Pleural nodularity
No 77 (19) — — 1.00 —
Yes 22 (22) 2.45 0.001 135.05 —
WHO classification
Types A, AB, B1, and B2 77 (27)
Type B3 22 (14) 0.02 3.24 1.21–8.69
Gender
Male 53 (21) — — 1.00 —
Female 46 (20) 0.079 0.70 1.17 0.53–2.61
Age 99 (41) 0.030 0.04 0.97 0.94–0.999
ASA score
1–3 93 (37) — — 1.00 —
4–5 6 (4) 0.554 0.21 3.03 0.53–17.38
Myasthenia gravis
No 88 (36) — — 1.00 —
Yes 10 (5) 0.184 0.58 1.44 0.39–5.36
Weight lossc
No weight loss 65 (22) — — 1.00 —
Weight loss 26 (12) 0.258 1.68 0.66–4.23
a Tumor size was measurable in 98 patients.
b For the variable lymphadenopathy, logistic regression model did not produce a valid model result.
c Weight loss data were available for 91 patients.
CT, computed tomography; CI, confidence interval; ASA, American Society of Anesthesiologist; WHO, World Health Organization.
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pleural nodularity (p  0.0001), stage III/IV at presentation
(p  0.0001), and type B3 tumor (p  0.02) were associated
with progression of disease. Nevertheless, on multivariable
analysis, only the presence of pleural nodularity (HR: 3.73;
95% CI: 1.52–9.12; p  0.004), type B3 tumor (HR: 2.77;
95% CI: 1.20–6.41; p  0.02), and stage III/IV disease (HR:
5.75; 95% CI: 1.49–22.12; p  0.01) were associated with
disease progression.
The only imaging variable associated with worse over-
all survival in Cox’s proportional hazard model was the
presence of pulmonary nodules (p  0.03). Clinical patient
variables, other imaging variables, tumor type, and stage
were not associated with overall survival. A 50% nomo-
gram probability of having stage III/IV disease was asso-
ciated with a shorter progression-free survival (p  0.005)
(Figure 5) but was not associated with overall survival
(p  0.66).
DISCUSSION
We have found that the CT appearance of the primary
tumor is useful in distinguishing stage I or II thymomas from
stage III or IV disease. The preoperative CT features of larger
tumor size, lobulated tumor, and infiltration of fat surround-
ing the tumor suggest a high probability of Masaoka stage III
or IV disease. When a patient with normal appearing pleura
presents, tumor heterogeneity and infiltration of the surround-
ing fat are most associated with stage III disease.
FIGURE 1. Fifty-nine-year-old woman with stage IIb thy-
moma. Contrast-enhanced chest computed tomography
(CT) scan demonstrates a 4.5-cm anterior mediastinal mass
(arrow) that is round, is well demarcated, and does not infil-
trate the surrounding fat. At surgery, microscopic tumor in-
vasion of the capsule was found. A, ascending aorta. P, main
pulmonary artery.
FIGURE 2. Sixty-one-year-old man with stage III thymoma.
Contrast-enhanced chest computed tomography (CT) scan
demonstrates an 8.5-cm anterior mediastinal mass (arrow)
that is lobulated, is poorly demarcated, does not infiltrate
the surrounding fat, and abuts 50% of the circumference
of the ascending aorta (A). At surgery, the tumor was found
to invade the pleura, lung parenchyma, and innominate
vein. P, left pulmonary artery.
FIGURE 3. Nomogram to predict stage III/IV thymoma us-
ing computed tomography (CT) findings at presentation.
The nomogram consists of six rows. Row 1 (points row) is
the point assignment for each variable. Rows 2 to 4 corre-
spond to the variables included in the model. For an individ-
ual patient, each variable in rows 2 to 4 is assigned a point
value, which is determined by drawing a vertical line from
the appropriate position on the variable row to the points
row. The assigned points for all three variables are added,
and the total is marked on row 5 (shaded row called: total
points). Then, the probability of having stage III/IV disease is
calculated by drawing a vertical line from the appropriate
position on the total points row to the row 6, which shows
the probability of stage III or IV disease. Thus, for a patient
with a lobular, larger than 7 cm tumor, which infiltrates the
surrounding fat, the points added would be 100, 55, and 63
points, respectively, which adds to 218 total points or a
75% probability of having stage III/IV disease. The concor-
dance index of this nomogram is 0.804. After internal vali-
dation using 200 bootstrap samples, the bias-corrected con-
cordance index was 0.795 with an optimism of 0.009. Using
this point system, total points 164 predict a 50% proba-
bility of having stage III/IV disease.
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Previous studies have assessed whether thymoma size
at surgery is associated with long-term survival. The smaller
studies did not find a correlation between tumor size and
overall survival,7,16 whereas the larger studies found that
larger tumors were more likely to recur.3,17,18 In our study,
larger tumors were not associated with overall or progression-
free survival.
The few prior studies that focused on the CT appear-
ance of thymoma found that CT could not distinguish be-
tween the different WHO histologic subtypes of thymo-
mas.19–22 This may be due to inherent problems with the
WHO classification system for thymoma, rather than due to
the imaging itself.2 The interobserver and intraobserver re-
producibility for interpreting pathologists can be poor with
the WHO system.23 To complicate matters, thymomas are
characterized by morphologic heterogeneity. Thus, several
WHO subtypes often coexist in the same tumor, making it
difficult to assign a tumor classification, particularly on the
basis of a preoperative needle biopsy specimen that may not
have sampled the areas of the tumor with the predominant
subtype.2 By using a modified WHO system,2,13 we were able
to show a correlation of tumor size with histologic classifi-
cation. In addition, the WHO classification system cannot be
used to predict clinical outcome23–25 but with the modified
system was found to be associated with progression-free
survival.
We chose to compare our CT findings to stage deter-
mined using the Masaoka staging system, which has been
shown to be an independent predictor of recurrence and
long-term survival.3,18,26 To our knowledge, only two previ-
ous studies examined the relationship of the CT appearance
of thymoma to the Masaoka stage.27,28a In those studies, the
authors examined whether CT appearance could distinguish
stage I disease from higher stages. The researchers were able
to identify some CT findings that were more common in
invasive thymomas, such as lobulated contours, irregular
contours, and larger tumor size; but these features were also
seen—though generally to a lesser degree–in a substantial
number of the encapsulated thymomas they assessed. In
contrast, we assessed whether CT could distinguish stage I/II
disease from stage III/IV.
There have been no prospective randomized controlled
trials providing level I evidence on the best therapeutic
approach to thymoma. There is consensus that stage I thy-
momas can be treated with surgery alone, with no adjuvant
therapy, because completely resected stage I thymomas have
only a 0.9% overall recurrence risk and are associated with a
5-year overall survival rate of 100%.26,28,29 At present, how-
ever, there is individual and institutional variation in the
sequencing of treatment for higher stages of thymoma (stages
II–IV). For completely resected stage II disease, radiation
and/or chemotherapy given as neoadjuvant therapy and/or
adjuvant therapy are not recommended.26,28 Nevertheless,
despite the fact that radiation therapy after complete resection
of stage II disease has not been shown to make a difference
in disease-free or overall survival,30,31 some institutions do
administer radiation therapy because of older data showing
that stage II disease has a higher risk of local recurrence than
stage I disease.32 Furthermore, some patients with stage II
disease may receive neoadjuvant therapy because imaging
techniques have historically not been able to reliably detect
vessel involvement and thus distinguish stage II from stage
III disease. Unlike for stage II disease, neoadjuvant therapy
FIGURE 4. Receiver operating characteristic curve of our
nomogram showing that the nomogram predicts stage III/IV
disease very well, with the area under the curve or concor-
dance index of 80.
FIGURE 5. Kaplan-Meier estimate of progression-free sur-
vival according to the nomogram-predicted probability of
having stage III/IV disease (p  0.005).
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for stage III disease has been shown to be beneficial and is
recommended.8–10,26,28,33 Thus, a means of preoperatively
identifying those patients who can benefit from neoadjuvant
therapy—those with stage III or IV disease—is necessary.
The nomogram proposed in our study creates a simple way to
generate an individual’s probability of having stage III/IV
disease. With internal validation of the nomogram performed
using 200 bootstrap samples, we obtained a bias-corrected
concordance index of 0.795 with an optimism of 0.009,
suggesting clinical accuracy of the nomogram.
Although further validation is needed, we are hopeful
that our nomogram will enable patients who will not benefit
from neoadjuvant therapy—those with stage I/II disease—to
be spared the potential harm that accompanies it. Patients
with thymoma have high 5- and 10-year overall survival
rates, so the likelihood of suffering long-term adverse effects
from unnecessary radiation and/or chemotherapy cannot be
overlooked.34 The potential complications from these thera-
pies include cardiac damage and secondary malignancies.
Even with the newer radiation techniques (such as three-
dimensional conformal radiation, intensity-modulated radia-
tion therapy, and proton therapy) currently used to decrease
the radiation dose to surrounding normal tissues, irradiation
of the heart cannot always be avoided as thymomas often abut
the heart. Patients whose hearts are exposed to radiation are
known to suffer from cardiomyopathy and accelerated coro-
nary artery disease, and these effects can be increased by the
addition of chemotherapy.35–45 Neoadjuvant chemotherapy
can be cardiotoxic as well and can lead to cardiomyopathy.46
Secondary malignancies are seen in up to 28% of long-term
thymoma survivors.5 Although it is not clear whether this is
due to treatment or to other thymoma-associated factors,
secondary solid tumors in thymoma survivors occur most
often within the radiation field.47
Our study has the usual limitations of a retrospective
study. In addition, the population size is rather small but
reflects the rarity of thymoma. Although some patients re-
ceived neoadjuvant therapy before surgical staging, which
affected tumor size in some, the tumor size association with
the risk of having stage III/IV thymoma persisted. The fact
that only pulmonary nodules were associated with poor over-
all survival may be due to the fact that only 10 patients died
in our study; the power to detect meaningful associations
between any factor and overall survival was therefore fairly
low. The relatively short follow-up period may also have
affected our ability to detect overall survival associations.
Even patients with locally aggressive thymoma (stage III)
have up to a 60% 10-year overall survival rate.26 To over-
come the issue of the rarity of this disease, the International
Thymic Malignancy Interest Group was recently formed,
through which we plan to validate our nomogram in a
multiinstitutional study. We hope that this will provide a
deeper understanding of thymoma and lead to evidence-based
imaging and treatment of this disease.
In conclusion, CT imaging of thymoma may be useful
to distinguish between stage I/II and stage III/IV thymoma.
Although further validation is needed, we hope our findings
will ultimately enable physicians to determine at presentation
which patients with thymoma will benefit from neoadjuvant
therapy and which will not.
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Erratum
Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms: Erratum
In the article that appeared on page 1826 of the November 2010 issue, an author’s academic degree was incorrect. The author’s name should have
appeared as Constance Johnson, PhD.
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